Facilitated By

San Antonio Medical Foundation

A PHASE III, OPEN-LABEL EXTENSION TRIAL OF ECU-MG-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (gMG)

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Bhavaraju-Sanka,Ratna K.
Funded by
ALEXION PHARMACEUTICALS
Research Start Date
Status
Inactive
Clinical Care
Drug Discovery
Neuroscience